European Medicines Agency to review tralokinumab for atopic dermatitis

Tralokinumab is a fully human monoclonal antibody that binds to and neutralises interleukin-13. The marketing authorisation application is based on data from the ECZTRA 1, 2 and 3 Phase III studies.

PharmaTimes